286 results on '"Benedet, Andréa Lessa"'
Search Results
2. Biomarker-based staging of Alzheimer disease: rationale and clinical applications
3. Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer’s pathology
4. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts
5. Equivalence of plasma p‐tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease
6. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography
7. Tau phosphorylation is more closely associated with amyloid‐β plaques than with tau neurofibrillary tangles
8. Brain TSPO expression is associated with plasma pTau181 & pTau231 across the AD spectrum
9. Different criteria modify Alzheimer’s disease diagnosis and prognosis
10. A head‐to‐head comparison of plasma phosphorylated tau assays in the real‐world memory clinic
11. Comparison of plasma amyloid, tau, and astrocyte biomarkers to identify AD pathophysiology
12. pTau heterogeneity as a measure for disease severity in incipient Alzheimer's disease
13. TRIAD multi‐dimensional biobank for biomarker discovery
14. Role of astrogliosis in the relationship between cerebrovascular burden and Alzheimer’s disease pathology
15. Association between tau uptake and verbal fluency converge in language centers
16. Simultaneous Mass Spectrometric quantification of multiple p‐tau species in plasma – findings along the Alzheimer´s disease continuum
17. Amyloid and tau pathologies associate with distinct aspects of the inflammatory cascade
18. Impact of meningeal and age‐related off‐target binding on longitudinal [18F]MK6240 quantification
19. Impact of meningeal and age‐related off‐target binding on longitudinal [ 18 F]MK6240 quantification.
20. Neuropathological validation of plasma GFAP
21. Biomarker modelling of Alzheimer's disease using in vivo Braak staging
22. Longitudinal changes in plasma p‐tau181 as a surrogate variable to populational interventions
23. Apolipoprotein E ε4 associates with microglial activation in early Braak regions independently of amyloid‐β and tau
24. Associations between neutrophils and amyloid deposition in the Alzheimer’s disease spectrum
25. Visual memory test equal to commonly used verbal memory test in predicting tau in the medial temporal lobe
26. Discrepancy between plasma pTau181 and tau‐PET statuses
27. Plasma p‐Tau181 and p‐Tau231 offer complementary information to identify Alzheimer's disease pathophysiology
28. Tau accumulation using [18F]MK6240 PET is associated with increase in executive dysfunction in prodromal AD
29. Tau368 in cerebrospinal fluid is associated with severity of tau pathology load in the Alzheimer’s continuum
30. Effect of temporal meta‐ROI and Braak1&2 ROI on the dissociation between plasma pTau181 and PET statuses
31. Verbal fluency associated with tau accumulation and not amyloid deposition in the Alzheimer’s disease spectrum
32. Microglial activation and tau propagate jointly across Braak stages
33. COVID‐19 pandemic: Quantifying the effects of the first lockdown on behavioral and cognitive measures using TASIC
34. Tau‐load in the lingual gyrus impacts anxiety levels during the COVID‐19 pandemic in participants of longitudinal observational studies in aging
35. Visual memory scores are associated with lateralization of tau in the medial temporal lobe
36. Association of tau pathology and vascular risk factor burden with longitudinal measures of plasma neurofilament light
37. Cognitive reserve: Evaluating the relationship between WASI‐II Matrix Reasoning and tau accumulation using [18F]MK6240 in monolingual and bilingual individuals
38. The neuroinflammation signatures in different stages of the Alzheimer’s disease continuum
39. Plasma p‐tau231 in the Alzheimer’s disease continuum: A multi‐cohort evaluation of diagnostic performance, detection of Aβ pathology and preclinical application
40. Mass spectrometric measurement of six site‐specific tau phosphorylations in CSF and blood of Alzheimer's disease patients
41. Clinical relevance of three‐range cutpoints in Alzheimer’s disease CSF biomarkers
42. Plasma biomarkers associations with cognitive change in preclinical Alzheimer's disease.
43. Intrinsic connectivity of the human brain provides scaffold for tau aggregation in clinical variants of Alzheimer's disease
44. Serum cholesterol levels and APOEε4 status potentiate metabolic decline in non‐demented individuals
45. Cerebrospinal fluid tau biomarkers in the prediction and concordance of neurofibrillary tangle and amyloid pathology
46. Tau deposition assessed by [ 18 F]MK6240 PET is associated with longitudinal decrease in grey matter density across the spectrum of Alzheimer’s disease
47. Interaction between amyloid and neuroinflammation on apathy along the Alzheimer’s disease spectrum
48. Quantification of tau phosphorylated at threonine 217 using a novel ultrasensitive immunoassay distinguishes Alzheimer’s disease from healthy controls
49. [ 18 F]MK‐6240 depicts early and late Braak stages of neurofibrillary tangles in preclinical and symptomatic subjects
50. Association between left hemisphere MK6240 uptake and language dysfunction in aging and Alzheimer’s disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.